MedTech & Diagnostics
KORU Medical Systems Executive Compensation (FY25)
KRMD · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Linda Tharby | Latest say-on-pay support = May 19, 2026 |
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The KORU Medical Systems brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of October 27, 2026Latest filing (8-K): May 21, 2026
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
163 figures on this page: 153 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Linda Tharby: $1,271,525 → $1,737,883 (36.7% higher)
Say-on-pay support: 97.1% → 99.6% (2.5 points higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is KORU Medical Systems' chief executive and what were they paid?
Linda Tharby was paid $1,737,883 in total compensation as Chief Executive Officer for fiscal 2025. Compared with the $1,271,525 reported for fiscal 2024, Tharby's total was 36.7% higher.
What was KORU Medical Systems' say-on-pay result?
Shareholders supported the say-on-pay proposal with 99.6% of votes cast for or against in favor at the meeting held May 19, 2026 for fiscal 2025.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Brian Case Chief Technology Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Linda Tharby President & CEO | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
Thomas Adams Chief Financial Officer | ◇ | ◇ | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kenneth Miller Chief Commercial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Linda Tharby President & CEO | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
Thomas Adams Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Brian Case Chief Technology Officer | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Linda Tharby President & CEO | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Brian Case Former Chief Technology Officer Departed during or after this year | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
Thomas Adams Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Kenneth Miller Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Adam Kalbermatten Chief Commercial Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Linda Tharby Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Thomas Adams Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | — not reconciled |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Adam Kalbermatten | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Adam Kalbermatten | Option | ◇ | — | ◇ | 8/1/2035 |
| RSU | ◇ | ◇ | — | — | |
| Linda Tharby | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/15/2034 | |
| Option | ◇ | — | ◇ | 5/12/2035 | |
| Thomas Adams | PSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 5/12/2035 | |
| Option | ◇ | — | ◇ | 7/30/2033 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/15/2034 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
R. John Fletcher Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Robert A. Cascella | ◇ | ◇ | — | — | — | — | ◇ |
Joseph M. Manko Jr | ◇ | ◇ | — | — | — | — | ◇ |
Shahriar (Shar) Matin | ◇ | ◇ | — | — | — | — | ◇ |
Edward Wholihan | ◇ | ◇ | — | — | — | — | ◇ |
Donna French | ◇ | ◇ | — | — | — | — | ◇ |
Linda Tharby served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Equity is delivered as Common Stock.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 19, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 14, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 9, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 17, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 6, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 18, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | April 22, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | April 23, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | April 23, 2018 | = | ◇ | ◇ | ◇ |
| 2015 | September 6, 2016 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Linda Tharby (Chief Executive Officer), FY2025 total compensation $1,737,883 (base salary $596,960) [exec_comp, SEC accession 0001161697-26-000091, filed 2026-04-09]What this page does not include
Everything above is a fact KORU Medical Systems disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
163 figures on this page: 153 cited to the filing that reported them, 10 calculated from figures it prints.
153 cited to the filing
10 calculated from the filing
Documents cited
- 0001161697-26-000128Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001161697-26-000091
- 0001161697-25-000173Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001161697-25-000139
- 0001161697-24-000230Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001161697-24-000162
- 0001161697-23-000302Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001161697-23-000194
- 0001161697-22-000232Item 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- 0001161697-21-000276ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- 0001161697-20-000164ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- 0001161697-19-000153ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- 0001161697-18-000218ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- 0001161697-16-001070ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “KORU Medical Systems executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/KRMD (accessed 2026).
Short form: data: Velarion
The KORU Medical Systems brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about KORU Medical Systems and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}